The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines

Richard Weiten, Theadora Engler, Hubert Schorle, Jörg Ellinger, Miriam Saponaro, Abdullah Alajati, Daniel Nettersheim, Isabella Syring‐Schmandke · 2024

Read The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines by Richard Weiten, Theadora Engler, Hubert Schorle, Jörg Ellinger, Miriam Saponaro, Abdullah Alajati, Daniel Nettersheim, Isabella Syring‐Schmandke (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11661915.txt.

Description

Richard Weiten and co-authors test whether a small RNA marker also drives drug resistance in testicular cancer, in a 2024 study. The marker, a microRNA, is a new blood test for these tumours and is raised in cell lines that resist cisplatin, a standard chemotherapy drug. No one had tested what the marker itself does to drug response.

Blocking the marker cut its level by more than ninety-eight percent. After that block, both resistant and normal tumour cell lines became far more sensitive to cisplatin. Fewer cells survived and more cells entered a death program. The authors suggest the marker helps tumours develop resistance to the drug. Targeting the marker could be a way to restore drug response in patients whose tumours no longer react, a group with few options left.

Catalog record

CREATORRichard Weiten, Theadora Engler, Hubert Schorle, Jörg Ellinger, Miriam Saponaro, Abdullah Alajati, Daniel Nettersheim, Isabella Syring‐Schmandke
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11661915

Browse the full library · About the Tower of Babel